You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for New Drug Application (NDA): 206910


✉ Email this page to a colleague

« Back to Dashboard


NDA 206910 describes JADENU, which is a drug marketed by Novartis Pharms Corp and Novartis and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the JADENU profile page.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 206910
Tradename:JADENU
Applicant:Novartis Pharms Corp
Ingredient:deferasirox
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 206910
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0654 0078-0654-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15)
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0655 0078-0655-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength90MG
Approval Date:Mar 30, 2015TE:ABRLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Nov 21, 2034Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength180MG
Approval Date:Mar 30, 2015TE:ABRLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Nov 21, 2034Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength360MG
Approval Date:Mar 30, 2015TE:ABRLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Nov 21, 2034Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 206910

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-001 Mar 30, 2015 ⤷  Try a Trial ⤷  Try a Trial
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-003 Mar 30, 2015 ⤷  Try a Trial ⤷  Try a Trial
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-001 Mar 30, 2015 ⤷  Try a Trial ⤷  Try a Trial
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-003 Mar 30, 2015 ⤷  Try a Trial ⤷  Try a Trial
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 ⤷  Try a Trial ⤷  Try a Trial
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.